Progyny (NASDAQ:PGNY – Get Free Report) updated its second quarter 2024 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.390-0.410 for the period, compared to the consensus estimate of 0.180. The company issued revenue guidance of $300.0 million-$310.0 million, compared to the consensus revenue estimate of $335.8 million. Progyny also updated its FY 2024 guidance to 1.610-1.680 EPS.
Progyny Price Performance
PGNY stock traded up $0.34 during mid-day trading on Thursday, reaching $32.50. The company had a trading volume of 1,646,876 shares, compared to its average volume of 800,912. The company has a market capitalization of $3.12 billion, a PE ratio of 52.42, a price-to-earnings-growth ratio of 1.31 and a beta of 1.51. Progyny has a 12 month low of $29.44 and a 12 month high of $44.95. The firm has a 50 day moving average of $34.75 and a 200 day moving average of $35.61.
Progyny (NASDAQ:PGNY – Get Free Report) last released its quarterly earnings results on Tuesday, February 27th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.04. Progyny had a net margin of 5.70% and a return on equity of 12.64%. The business had revenue of $269.94 million for the quarter, compared to analyst estimates of $274.08 million. During the same period in the previous year, the company earned $0.03 earnings per share. The business’s revenue for the quarter was up 26.0% on a year-over-year basis. Analysts anticipate that Progyny will post 0.7 EPS for the current year.
Wall Street Analysts Forecast Growth
Check Out Our Latest Research Report on Progyny
Insider Buying and Selling
In other news, CFO Mark S. Livingston sold 11,165 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $37.62, for a total transaction of $420,027.30. Following the completion of the transaction, the chief financial officer now directly owns 50,119 shares of the company’s stock, valued at approximately $1,885,476.78. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Chairman David J. Schlanger sold 5,826 shares of the company’s stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $37.74, for a total transaction of $219,873.24. Following the completion of the sale, the chairman now directly owns 86,312 shares of the company’s stock, valued at approximately $3,257,414.88. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Mark S. Livingston sold 11,165 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $37.62, for a total value of $420,027.30. Following the completion of the transaction, the chief financial officer now directly owns 50,119 shares in the company, valued at $1,885,476.78. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 102,770 shares of company stock valued at $3,853,985. 12.30% of the stock is owned by insiders.
About Progyny
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Featured Articles
- Five stocks we like better than Progyny
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Roblox: The Bottom Just Fell Out of the Metaverse
- Are Penny Stocks a Good Fit for Your Portfolio?
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- What Are Trending Stocks? Trending Stocks Explained
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.